Background: In carcinogenesis, methylation of DNA promoter regions results in inactivation of tumor-suppressing genes. MG98 was designed to inhibit DNA methyltransferases enzyme 1 production.
Methods: This multicenter study explored two schedules of MG98 with Interferon-α-2β to identify schedule and dose for patients with metastatic RCC.
Results: Doses of IFN 9 MIU/MG98 125 mg/m(2) for a continuous schedule and IFN 9 MIU/MG98 200 mg/m(2) for an intermittent schedule were considered the MTDs. Treatment resulted in one PR and eight SD.
Conclusion: MG98 combined with IFN was safe and resulted in clinical activity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/07357907.2012.675381 | DOI Listing |
Publication Analysis
Top Keywords
ifn miu/mg98
8
mg98
4
mg98 second-generation
4
second-generation dnmt1
4
dnmt1 inhibitor
4
inhibitor treatment
4
treatment advanced
4
advanced renal
4
renal cell
4
cell carcinoma
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!